معرفی
Hwangseo Park is a Professor in the Department of Integrative Bioscience and Biotechnology at Sejong University, with an active research profile evidenced by 144 publications and an h-index of 35. Current research output spans from 1997 to 2025, showing sustained productivity with 5 publications in 2025 alone.
Research focuses on computational drug discovery and structural biology, particularly targeting enzyme inhibition mechanisms. Key areas include virtual screening, protein tyrosine phosphatase modulation, de novo drug design, and nanobody-based therapeutics. The fingerprint analysis reveals dominant work in pharmacology (100% Virtual Screening), biochemistry (52% Active Site studies), and molecular biology (46% Phosphatase research).
Recent publications demonstrate strong translational impact, with 2025 papers covering
- Pancreatic cancer therapy via mesothelin-targeting nanobodies (cited 2 times)
- CD155-targeted lung adenocarcinoma treatment (6 news mentions)
- Vaspin-AP-1 axis blockade for arthritis (featured in news outlets)
- IRAK4 inhibitor optimization for anti-inflammatory applications
- Green space health impact analysis using digital tracking
No formal awards are documented in the provided materials. Research activities involve significant international collaboration, with network visualizations indicating multi-country partnerships in pharmacology and biochemistry domains. Current projects emphasize nanobody engineering for precision oncology and computational optimization of drug candidates.
